Paredes R - Search Results

1

Cancer immunotherapy in special challenging populations: recommendations of the Advisory Committee of Spanish Melanoma Group (GEM).

Gonzalez-Cao M, Puertolas T, Riveiro M, Muñoz-Couselo E, Ortiz C, Paredes R, Podzamczer D, Manzano JL, Molto J, Revollo B, Carrera C, Mateu L, Fancelli S, Espinosa E, Clotet B, Martinez-Picado J, Cerezuela P, Soria A, Marquez I, Mandala M, Berrocal A; Spanish Melanoma Group (GEM). Gonzalez-Cao M, et al. Among authors: paredes r. J Immunother Cancer. 2021 Mar;9(3):e001664. doi: 10.1136/jitc-2020-001664. J Immunother Cancer. 2021. PMID: 33782108 Free PMC article. Review.

2

The potential role of interleukin-2 in patients with HIV infection.

Paredes R, López Benaldo de Quirós JC, Fernández-Cruz E, Clotet B, Lane HC. Paredes R, et al. AIDS Rev. 2002 Jan-Mar;4(1):36-40. AIDS Rev. 2002. PMID: 11998783 Review.

3

Reversal of atherogenic lipoprotein profile in HIV-1 infected patients with lipodystrophy after replacing protease inhibitors by nevirapine.

Negredo E, Ribalta J, Paredes R, Ferré R, Sirera G, Ruiz L, Salazar J, Reiss P, Masana L, Clotet B. Negredo E, et al. Among authors: paredes r. AIDS. 2002 Jul 5;16(10):1383-9. doi: 10.1097/00002030-200207050-00010. AIDS. 2002. PMID: 12131215 Clinical Trial.

4

Role of structured treatment interruption before a 5-drug salvage antiretroviral regimen: the Retrogene Study.

Ruiz L, Ribera E, Bonjoch A, Romeu J, Martinez-Picado J, Paredes R, Díaz M, Marfil S, Negredo E, García-Prado J, Tural C, Sirera G, Clotet B. Ruiz L, et al. Among authors: paredes r. J Infect Dis. 2003 Oct 1;188(7):977-85. doi: 10.1086/378411. Epub 2003 Sep 23. J Infect Dis. 2003. PMID: 14513417 Clinical Trial.

5

New antiretroviral drugs and approaches to HIV treatment.

Paredes R, Clotet B. Paredes R, et al. AIDS. 2003;17 Suppl 4:S85-96. doi: 10.1097/00002030-200317004-00010. AIDS. 2003. PMID: 15080184 Review. No abstract available.

6

Unexpected CD4 cell count decline in patients receiving didanosine and tenofovir-based regimens despite undetectable viral load.

Negredo E, Moltó J, Burger D, Viciana P, Ribera E, Paredes R, Juan M, Ruiz L, Puig J, Pruvost A, Grassi J, Masmitjà E, Clotet B. Negredo E, et al. Among authors: paredes r. AIDS. 2004 Feb 20;18(3):459-63. doi: 10.1097/00002030-200402200-00012. AIDS. 2004. PMID: 15090798

7

[Duration of antiretroviral combinations].

Paredes R, Clotet B. Paredes R, et al. Med Clin (Barc). 2004 May 15;122(18):696-7. doi: 10.1016/s0025-7753(04)74359-6. Med Clin (Barc). 2004. PMID: 15171830 Spanish. No abstract available.

8

Alternation of antiretroviral drug regimens for HIV infection. Efficacy, safety and tolerability at week 96 of the Swatch Study.

Negredo E, Paredes R, Peraire J, Pedrol E, Côté H, Gel S, Fumoz CR, Ruiz L, Abril V, Rodriguez de Castro E, Ochoa C, Martinez-Picado J, Montaner J, Rey-Joly C, Clotet B; Swatch Study Team. Negredo E, et al. Among authors: paredes r. Antivir Ther. 2004 Dec;9(6):889-93. Antivir Ther. 2004. PMID: 15651747 Clinical Trial.

9

Reversal of HIV-1-associated osteoporosis with once-weekly alendronate.

Negredo E, Martínez-López E, Paredes R, Rosales J, Pérez-Alvarez N, Holgado S, Gel S, del Rio L, Tena X, Rey-Joly C, Clotet B. Negredo E, et al. Among authors: paredes r. AIDS. 2005 Feb 18;19(3):343-5. AIDS. 2005. PMID: 15718847 Clinical Trial.

10

Compromised immunologic recovery in treatment-experienced patients with HIV infection receiving both tenofovir disoproxil fumarate and didanosine in the TORO studies.

Negredo E, Bonjoch A, Paredes R, Puig J, Clotet B. Negredo E, et al. Among authors: paredes r. Clin Infect Dis. 2005 Sep 15;41(6):901-5. doi: 10.1086/432879. Epub 2005 Aug 15. Clin Infect Dis. 2005. PMID: 16107993 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

717 results

Search Page